Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

26.47 -0.15 (-0.56%)
Streaming Delayed Price Updated: 2:11 PM EST, Dec 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
Dow Jumps 200 Points Following Fed Decision; Pfizer Earnings Top Estimates
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
US Stocks Mixed Ahead Of Fed Meeting, Chipmakers Tumble After AMD Earnings, Bitcoin Sinks: What's Driving Markets Wednesday?
Traders are treading cautiously in Wednesday’s session, seeking more clarity on the Federal Reserve’s stance with inflation reports exceeding expectations. 
Via Benzinga
Topics Economy
Exposures Interest Rates
PFE Stock Earnings: Pfizer Beats EPS, Beats Revenue for Q1 2024
PFE stock results show that Pfizer beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
(PFE) - Analyzing Pfizer's Short Interest
Via Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Exposures US Equities
Pfizer Q1 Earnings and Revenues Beat Estimates
PFE came out with quarterly earnings of $0.82 per share, beating the our eimate of $0.56 per share. This compares to earnings of $1.23 per share a year ago. 
Via Talk Markets
Pfizer Embraces Direct-To-Consumer Model For Covid Antiviral, Says Comirnaty Revenues Continue To Perform Consistently With Expectations
Pfizer reports Q1 results: adjusted EPS beats estimates, driven by revenue growth. Significant declines in Comirnaty and Paxlovid revenues countered by operational gains. Company announces plans for... 
Via Benzinga
Exposures COVID-19
GSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook
Discover GSK's first-quarter performance, boasting a 10% Y/Y sales surge to £7.4 billion. Notable growth in Vaccines and Specialty Medicines, propelled by strong demand for Arexvy and Shingrix.... 
Via Benzinga
Pfizer Jumps After Raising Its Outlook On The Heels Of A Big Quarterly Beat
The company raised its earnings outlook for the year, noting it's on track to save at least $4 billion in net costs. 
Via Investor's Business Daily
Pfizer Reports First-Quarter 2024 Results
From Pfizer Inc.
Via Business Wire
Wall Street Set To Open Lower After AMD Earnings Disappoint As Traders Look To Fed's Powell For Relief: Why This Analyst Sees Incoming Summer Rally
A negative sentiment might linger on Wall Street on Wednesday, as evidenced by stock futures, after Advanced Micro Devices, Inc.‘s (NASDAQ:AMD) 
Via Benzinga
Topics Economy
Exposures Interest Rates
Investor Sentiment Falls, Dow Snaps Five-Month Win Streak
Via Benzinga
Topics Stocks
Exposures US Equities
Amazon, Pfizer And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
7 Safe Haven Stocks That Can Withstand the Market’s Worst Meltdowns
Safe haven stocks offer stability even during market fall in communication, financials, healthcare, energy and consumer staples. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Pfizer Sees Less Revenue From Covid-19 Treatments, Stock Faces Headwinds Ahead Of Q1 Earnings
Pfizer's Q1 earnings report expects EPS of 49 cents and $13.09 billion in revenues. Stock has declined 34.61% YoY and -10.94% YTD due to COVID-19 revenue decrease. Technical analysis shows bearish... 
Via Benzinga
Exposures COVID-19
5 Top Stocks to Buy in May
Whether you're looking for a proven player, passive income, or a breakout growth story, there are plenty of stocks worth buying this spring. 
Via The Motley Fool
Why I'm Buying This Beaten-Down, High-Yield Dividend Stock Hand Over Fist
The sun could be peeking through the dark clouds for Pfizer. 
Via The Motley Fool
Forget Nvidia: Prominent Billionaires Are Selling It and Buying These 2 Ultra-High-Yield Dividend Stocks Instead
Wall Street's brightest, most successful billionaire money managers are ditching Nvidia in favor of two time-tested income stocks with yields of 6.6%! 
Via The Motley Fool
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
From Pfizer Inc.
Via Business Wire
mRNA Is Promising A Breakthrough In Fighting Cancer
When it comes to cancer, there’s innovation both on the diagnostics and the treatment front thanks to messenger RNA, or mRNA, a genetic material we all got acquainted with during the COVID-19 era as it... 
Via Benzinga
Exposures COVID-19
3 Beaten-Down Stocks I Wouldn't Touch With a 10-Foot Pole
These stocks aren't bargains. 
Via The Motley Fool
Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting
From Pfizer Inc.
Via Business Wire
3 Dividend Stocks to Buy on the Dip: April 2024
With the market presenting many vagaries, investors may take some solace in these dividend stocks to buy on the dip. 
Via InvestorPlace
Is Viking Therapeutics Incredibly Undervalued?
The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound. 
Via The Motley Fool
3 High-Yield Dividend Stocks That Could Soar 22% to 49%, According to Wall Street
Whether or not these stocks hit analysts' price targets, they all should be attractive to investors seeking great income and solid growth. 
Via The Motley Fool
3 Dividend Stocks to Buy and Hold for the Next Decade
You'll get dividends and more with these great stocks. 
Via The Motley Fool
7 Dividend Stocks to Buy Now for Steady Returns in Any Market
Passive investors pay attention! Invest in the best of the best with these seven dividend stocks for steady returns. 
Via InvestorPlace
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.